Risk of Malignancy in Uterine Fibroids
The overall risk of a presumed fibroid being malignant (leiomyosarcoma) is approximately 0.3% (3 per 1,000), but this risk increases significantly with age, reaching up to 1% (10 per 1,000) in women aged 75-79 years 1.
Age-Stratified Risk Assessment
The probability that a fibroid is actually a leiomyosarcoma varies dramatically by patient age:
- Women <30 years: Very low risk
- Women 40-60 years: Approximately 1% (8 per 817 cases in one series) 2
- Women 75-79 years: Up to 1% (10.1 per 1,000) 1
The baseline estimate from retrospective studies shows 2.94 per 1,000 (approximately 0.3%) risk of unexpected uterine sarcoma following surgery for presumed fibroids 1. However, a more recent study found the prevalence of unexpected malignancy to be 0.68% when including smooth muscle tumors of uncertain malignant potential (STUMP) 3.
Critical Clinical Red Flags
Continued fibroid growth or bleeding after menopause should raise immediate suspicion for uterine sarcoma 1. This is the single most important clinical warning sign that distinguishes malignancy from benign fibroids.
Additional concerning features include:
- Postmenopausal status with new or growing masses
- Rapid growth
- Abnormal uterine bleeding in older women
- Large tumor size (though size alone is not diagnostic)
Diagnostic Limitations
There is no way to definitively diagnose leiomyosarcoma versus fibroid prior to surgery 1. While MRI is useful for distinguishing between the two, it cannot provide definitive preoperative diagnosis. The 2024 ACR guidelines emphasize that fibroids and uterine sarcoma can present similarly 1.
Clinical Implications
Given the increased risk in postmenopausal women, all postmenopausal patients with abnormal uterine bleeding must undergo workup to rule out both endometrial cancer and uterine sarcoma prior to proceeding with minimally invasive treatments 1. This is particularly important because treatments like GnRH agonists, endometrial ablation, or myomectomy instead of hysterectomy could delay diagnosis and definitive treatment of leiomyosarcoma 2.
The absolute risk remains low overall (less than 1 in 1,000 cases) 4, and leiomyosarcomas are extremely rare, representing less than 1% of all uterine malignancies 5, 4. It remains unknown whether leiomyosarcoma represents de novo growth or malignant transformation from benign fibroids 4.